Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cyclacel Pharmaceuticals, Inc.
The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially or concomitantly. The secondary objectives are to evaluate antitumor activity of this sequential or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin and peripheral blood mononuclear cells.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Incurable advanced solid tumors that are no longer responding to conventional therapy or for which no effective therapy exists; at the RD of Part 1, an extension cohort up to 20 patients with metastatic breast cancer who are known to be BRCA mutation carriers will be enrolled.
Age 18 years or older
ECOG 0-2
Life expectancy ≥ 3 months
Evaluable disease
Adequate bone marrow function
Adequate renal function
Adequate liver function
At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
Able to swallow capsules
At least 3 weeks from major surgery
Agree to practice effective contraception
Ability to understand and willingness to sign the informed consent form
You may not be if
Previously untreated CNS metastases or progressive CNS metastases
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Uncontrolled intercurrent illness including
Pregnant or lactating women
Known to be HIV-positive
A history of active hepatitis B and/or hepatitis C infection
Clareo Health | A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
